Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Korea Stock Exchange  >  Boryung Pharmaceutical Co., Ltd.    A003850   KR7003850005


End-of-day quote. End-of-day quote Korea Stock Exchange - 11/26
19600 KRW   -5.31%
10/21S.Korea sticks to flu vaccine plan despite safety fears after 25 die
10/21Number of South Koreans dying after flu shot rises, prompts vaccine worries
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

S.Korea sticks to flu vaccine plan despite safety fears after 25 die

10/21/2020 | 11:47pm EST

SEOUL, Oct 22 (Reuters) - South Korean officials refused on Thursday to suspend a seasonal influenza inoculation effort, despite growing calls for a halt, including an appeal from a key group of doctors, after the deaths of at least 25 of those vaccinated.

Health authorities said they found no direct links between the deaths and the vaccines.

At least 22 of the dead, including a 17-year-old boy, were part of a campaign to inoculate 19 million teenagers and senior citizens for free, the Korea Disease Control and Prevention Agency (KDCA) said.

"The number of deaths has increased, but our team sees low possibility that the deaths resulted from the shots," the agency's director, Jeong Eun-kyeong, told parliament.

South Korea ordered a fifth more flu vaccines this year to ward off what it calls a "twindemic", or the prospect that people with flu develop coronavirus complications and overburden hospitals in winter.

"I understand and regret that people are concerned about the vaccine," said Health Minister Park Neung-hoo, who confirmed the free programme would go ahead.

"We're looking into the causes but will again thoroughly examine the entire process in which various government agencies are involved, from production to distribution."

Vaccine providers include domestic firms such as GC Pharma, SK Bioscience, Korea Vaccine and Boryung Biopharma Co. Ltd., a unit of Boryung Pharm Co. Ltd., along with France's Sanofi.

They supply both the free programme and paid services that together aim to vaccinate about 30 million of a population of 52 million.

Of the 25 dead, 10 received products from SK Bioscience, 5 each from Boryung and GC Pharma, one from Korea Vaccine and four from Sanofi.

All four domestic firms declined to comment, while Sanofi did not immediately reply to requests for comment.

It was not immediately clear if any of the vaccines made in South Korea were exported, or if those supplied by Sanofi were also being used elsewhere.

The Korean Medical Association, an influential grouping of doctors, urged the government to halt all inoculation programmes for now, to allay public concerns and ensure the vaccines were safe.

Kim Chong-in, leader of the main opposition People Power party, wanted the programme halted until the causes of the deaths were verified.

But health authorities have said a preliminary investigation into six deaths found no direct link to the vaccines, with no toxic substances uncovered.

KDCA data on Thursday showed at least seven of the nine people it investigated had underlying conditions.


The free programme has proved controversial since it began last month. The launch had been suspended for three weeks after the discovery that about 5 million doses were kept at room temperature rather than being refrigerated, as required.

Officials said 8.3 million people had been inoculated since the programme resumed on Oct. 13, with about 350 cases of adverse reactions reported.

A separate paid programme allows buyers to pick from a larger pool of firms that make free vaccines and others.

The most deaths in South Korea linked to seasonal flu vaccinations was six in 2005, the Yonhap news agency said. Officials have said comparisons to previous years are tough, since more people are taking the vaccine this year.

Kim Myung-suk, 65, is among a growing number of South Koreans who decided to pay for a vaccine of their choice, despite being eligible for a free dose.

"Though just a few people died so far, the number is growing and that makes me uneasy," she told Reuters in the capital, Seoul. "So I'm getting a shot somewhere else and will pay for it."

(Interactive graphic tracking global spread of coronavirus: https://graphics.reuters.com/world-coronavirus-tracker-and-maps/)

(Reporting by Hyonhee Shin; Additional reporting by Sangmi Cha, Dogyun Kim, Daewoung Kim and Heekyong Yang; Editing by Clarence Fernandez)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
BORYUNG PHARMACEUTICAL CO., LTD. -5.31% 19600 End-of-day quote.18.07%
GLAXOSMITHKLINE PLC -0.46% 1383.6 Delayed Quote.-22.23%
ILYANG PHARMACEUTICAL CO.,LTD 0.31% 64000 End-of-day quote.183.81%
LG CHEM, LTD. 3.55% 816000 End-of-day quote.157.01%
SANOFI -0.19% 85.21 Real-time Quote.-4.92%
10/21S.Korea sticks to flu vaccine plan despite safety fears after 25 die
10/21Number of South Koreans dying after flu shot rises, prompts vaccine worries
More news
Sales 2020 568 B 0,51 B 0,51 B
Net income 2020 30,1 B 0,03 B 0,03 B
Net Debt 2020 93,5 B 0,08 B 0,08 B
P/E ratio 2020 30,1x
Yield 2020 0,48%
Capitalization 939 B 850 M 850 M
EV / Sales 2020 1 654x
EV / Sales 2021 1 537x
Nbr of Employees 1 018
Free-Float 38,2%
Duration : Period :
Boryung Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BORYUNG PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 3
Average target price 20 333,33 KRW
Last Close Price 20 650,00 KRW
Spread / Highest target 11,4%
Spread / Average Target -1,53%
Spread / Lowest Target -7,99%
EPS Revisions
Sam-Soo Lee Co-Chief Executive Officer & Director
Jae-Hyeon Ahn Co-Chief Executive Officer & Director
Gwang-Sup Gil Independent Director
In-Goo Jeon Independent Director
Yoon-Sik Park Independent Director